药群论坛

 找回密码
 立即注册

只需一步,快速开始

查看: 2181|回复: 4
打印 上一主题 下一主题

[已回复] 文献

[复制链接]
跳转到指定楼层
楼主
巴黎精灵 发表于 2014-7-18 16:13:04 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式
2金币
In-vitro activity of flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins
这个文献我下不下了。急用,哪位大仙能帮忙

回复

使用道具 举报

沙发
feitian 发表于 2014-7-18 18:11:31 | 只看该作者
这个不好下
我只能下到摘要

In-vitro activity of flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins
Katsukiyo Yazawaa, Yuzuru Mikamia,*, Jun Unoa, Kiyotaka Otozaia and Tadashi Araib
+ Author Affiliations

aDepartment of Experimental Chemotherapy, Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University 1–8–1, Inohana, Chiba, Japan (280)
bBiotherapy Research Association 1–20–6, Mukougaoka, Bunkyo-ku, Tokyo, Japan (113)
*Corresponding author
Received May 5, 1989.
Accepted July 17, 1989.
Abstract

The susceptibility of 113 strains of pathogenic Nocardia, N. asteroides. N.farcinica, N. nova, N. brasiliensis and N. otitidiscaviarum to a new oxacephem antibiotic flomoxef was determined by an agar dilution method in comparison with those of 13 other cephalosporins. Flomoxef was two to 50 times more active against these pathogenic Nocardia than other cephalopsorins tested. However, there were differences in susceptibility to this antibiotic among these Nocardia strains. N. asteroides was the most sensitive species, followed by N.farcinica and N. nova. N. brasiliensis was moderately sensitive and N. otitidiscaviarum was resistant.
回复

使用道具 举报

板凳
论坛管理 发表于 2014-7-23 23:56:39 | 只看该作者
标示好 题目 作者  以及更多相关消息,更容易获得帮助!
回复

使用道具 举报

地板
 楼主| 巴黎精灵 发表于 2018-3-2 10:45:08 | 只看该作者
谢谢各位
回复

使用道具 举报

5#
shallow0551 发表于 2018-3-2 14:58:22 | 只看该作者
楼主还需要吗?附件不能上传了,见百度盘下载
链接:https://pan.baidu.com/s/1daj8kQ 密码:vaj0
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册  

本版积分规则

QQ|手机版|药群论坛 ( 蜀ICP备15007902号 )

GMT+8, 2024-11-29 11:01 AM , Processed in 0.082884 second(s), 17 queries .

本论坛拒绝任何人以任何形式在本论坛发表与中华人民共和国法律相抵触的言论! X3.2

© 2011-2014 免责声明:药群网所有内容仅代表发表者个人观点,不代表本论坛立场。

快速回复 返回顶部 返回列表